{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:21:27Z","timestamp":1791195687043,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20\u2013based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. 177Lu-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1\/2a study in 74 patients with relapsed\/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of 177Lu-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the \u201ccold\u201d anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3\/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1\/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with \u22652 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL \u22652 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). 177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed\/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. This trial was registered at www.clinicaltrials.gov as #NCT01796171.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002583","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T18:33:56Z","timestamp":1599071636000},"page":"4091-4101","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Phase 1\/2a study of 177Lu-lilotomab satetraxetan in relapsed\/refractory indolent non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"4","author":[{"given":"Arne","family":"Kolstad","sequence":"first","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Illidge","sequence":"additional","affiliation":[{"name":"University of Manchester, National Institutes of Health Research Manchester Biomedical Research Centre, Christie Hospital, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Spetalen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Madsbu","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-9635","authenticated-orcid":false,"given":"Caroline","family":"Stokke","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Physics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Blakkisrud","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Physics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayca","family":"L\u00f8ndalen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Oslo University Hospital, Radiumhospitalet, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0868-6417","authenticated-orcid":false,"given":"Noelle","family":"O'Rourke","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Beasley","sequence":"additional","affiliation":[{"name":"Bristol Cancer Institute, Bristol, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Institute of Oncology, Krak\u00f3w, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unn-Merete","family":"Fagerli","sequence":"additional","affiliation":[{"name":"St. Olav\u2019s Hospital and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Ka\u0161\u010d\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Bayne","sequence":"additional","affiliation":[{"name":"Dorset Cancer Centre, Poole, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3074","authenticated-orcid":false,"given":"Ale\u0161","family":"Obr","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-6005","authenticated-orcid":false,"given":"Jostein","family":"Dahle","sequence":"additional","affiliation":[{"name":"Nordic Nanovector ASA, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rojkjaer","sequence":"additional","affiliation":[{"name":"Nordic Nanovector ASA, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Pascal","sequence":"additional","affiliation":[{"name":"Nordic Nanovector ASA, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-9428","authenticated-orcid":false,"given":"Harald","family":"Holte","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"issue":"11","key":"2020090211382700000_B1","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"2020090211382700000_B2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"2020090211382700000_B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JBM.S190784","article-title":"How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas","volume":"10","author":"Mohammed","year":"2019","journal-title":"J Blood Med"},{"issue":"23","key":"2020090211382700000_B4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020090211382700000_B5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"2020090211382700000_B6","unstructured":"Food and Drug Administration. Gazyva prescribing information revised 3\/2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125486s025lbl.pdf. Accessed April 2020."},{"key":"2020090211382700000_B7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood-2019-131045","article-title":"A phase I\/II study of lenalidomide plus obinutuzumab in relapsed indolent lymphoma [abstract]","volume":"134","author":"Fowler","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020090211382700000_B8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14728214.2018.1479396","article-title":"Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rodgers","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6","key":"2020090211382700000_B9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"19","key":"2020090211382700000_B10","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020090211382700000_B11","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020090211382700000_B12","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020090211382700000_B13","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4049\/jimmunol.137.9.3013","article-title":"A unique antigen on mature B cells defined by a monoclonal antibody","volume":"137","author":"Link","year":"1986","journal-title":"J Immunol"},{"issue":"3","key":"2020090211382700000_B14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4049\/jimmunol.140.3.905","article-title":"The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein","volume":"140","author":"Schwartz-Albiez","year":"1988","journal-title":"J Immunol"},{"issue":"1","key":"2020090211382700000_B15","first-page":"85","article-title":"Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin\u2019s lymphoma","volume":"33","author":"Dahle","year":"2013","journal-title":"Anticancer Res"},{"issue":"6","key":"2020090211382700000_B16","doi-asserted-by":"crossref","first-page":"e0128816","DOI":"10.1371\/journal.pone.0128816","article-title":"Targeted cancer therapy with a novel anti-CD37 beta-particle emitting radioimmunoconjugate for treatment of non-Hodgkin lymphoma","volume":"10","author":"Repetto-Llamazares","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"2020090211382700000_B17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ejh.13139","article-title":"Combination of 177 Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin\u2019s lymphoma","volume":"101","author":"Repetto-Llamazares","year":"2018","journal-title":"Eur J Haematol"},{"issue":"9","key":"2020090211382700000_B18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00259-009-1120-2","article-title":"In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study","volume":"36","author":"Forrer","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2020090211382700000_B19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/cbr.2009.0641","article-title":"Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC","volume":"24","author":"Sierra","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"2020090211382700000_B20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-010-1631-x","article-title":"Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours","volume":"38","author":"Claringbold","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2020090211382700000_B21","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1007\/s00259-011-1833-x","article-title":"Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y\/177Lu-DOTATATE: which is a better therapy option?","volume":"38","author":"Kunikowska","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2020090211382700000_B22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2967\/jnumed.112.115170","article-title":"Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I\/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas","volume":"54","author":"Forrer","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"2020090211382700000_B23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2967\/jnumed.116.173922","article-title":"Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan","volume":"58","author":"Blakkisrud","year":"2017","journal-title":"J Nucl Med"},{"issue":"1","key":"2020090211382700000_B24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2967\/jnumed.116.180471","article-title":"Red marrow-absorbed dose for non-Hodgkin lymphoma patients treated with 177Lu-lilotomab satetraxetan, a novel anti-CD37 antibody-radionuclide conjugate","volume":"58","author":"Blakkisrud","year":"2017","journal-title":"J Nucl Med"},{"issue":"4","key":"2020090211382700000_B25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.117.195347","article-title":"Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-radionuclide conjugate 177Lu-lilotomab satetraxetan","volume":"59","author":"Blakkisrud","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"2020090211382700000_B26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00259-018-3964-9","article-title":"Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients","volume":"45","author":"Stokke","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2020090211382700000_B27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020090211382700000_B28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020090211382700000_B29","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.3390\/ph12040141","article-title":"Radioimmunotherapy in non-Hodgkin\u2019s lymphoma: Retrospective adverse event profiling of Zevalin and Bexxar","volume":"12","author":"Sachpekidis","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"2020090211382700000_B30","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"2020090211382700000_B31","unstructured":"Nordic Nanovector. 2018. Regulatory designations. https:\/\/www.nordicnanovector.com\/node\/324. Accessed March 2020."},{"key":"2020090211382700000_B32","unstructured":"Nordic Nanovector. 2020. Press releases. https:\/\/www.nordicnanovector.com\/investors-and-media\/press-releases?page=\/en\/pressreleases\/nordic-nanovector%2527s-betalutin%2528r%2529-receives-fast-track-designation-from-us-fda-for-marginal-zone-lymphoma-1822545. Accessed July 2020."},{"issue":"9","key":"2020090211382700000_B33","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdx392","article-title":"Revival of PI3K inhibitors in non-Hodgkin\u2019s lymphoma","volume":"28","author":"Batlevi","year":"2017","journal-title":"Ann Oncol"},{"key":"2020090211382700000_B34","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2147\/DDDT.S142406","article-title":"Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib","volume":"12","author":"Krause","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2020090211382700000_B35","unstructured":"Morschhauser F , TillyH, ChaidosA, et al. Interim update from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory (R\/R) follicular lymphoma (FL) [oral presentation at EHA23 2018]. Abstract S100. https:\/\/library.ehaweb.org\/eha\/2018\/stockholm\/214434\/gilles.salles.interim.update.from.a.phase.2.multicenter.study.of.tazemetostat.html?f=topic=1574*media=3%27. Accessed April 2020."},{"issue":"23","key":"2020090211382700000_B36","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020090211382700000_B37","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fonc.2019.01301","article-title":"The dual cell cycle kinase inhibitor JNJ-7706621 reverses resistance to CD37-targeted radioimmunotherapy in activated B cell like diffuse large B cell lymphoma cell lines","volume":"9","author":"R\u00f8dland","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"2020090211382700000_B38","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41375-019-0677-4","article-title":"The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2\/M cell cycle arrest","volume":"34","author":"Pichard","year":"2020","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/17\/4091\/1756975\/advancesadv2020002583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/17\/4091\/1756975\/advancesadv2020002583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T19:38:57Z","timestamp":1696621137000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/17\/4091\/463597\/Phase-12a-study-of-177Lulilotomab-satetraxetan-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":38,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002583","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]}}}